Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM300
- Development stage
- Preclinical
- Lead developer
- GlycoMantra
01
Overview
GM300 is a biologic drug candidate being developed by GlycoMantra for the treatment of lung fibrosis and idiopathic pulmonary fibrosis (IPF). As part of GlycoMantra's pipeline of glyco-biologics, GM300 is designed to target Galectin-3, a carbohydrate-binding protein that plays a central role in the development of tissue fibrosis by mediating fibroblast activation and extracellular matrix remodeling. By antagonizing Galectin-3, GM300 aims to disrupt the pathological processes underlying IPF and other fibrotic lung conditions. The candidate is currently in the early stages of development.
- Other names
- GM300 seriesGM-300 seriesGM 300 series
02
Targets
LGALS3 (Galectin-3)
Beyond the preview
Go deeper on GM300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM300.